Enrolling by invitationNot applicableNCT06374264
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
Studying Neuromyelitis Optica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- MedRhythms, Inc.
- Principal Investigator
- Eric Klawiter, MDMassachusetts General Hospital
- Intervention
- MR-C-014(device)
- Enrollment
- 30 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2024 – 2026
Study locations (2)
- Sheperd Center, Atlanta, Georgia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
Collaborators
Alexion Pharmaceuticals, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06374264 on ClinicalTrials.govOther trials for Neuromyelitis Optica
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05909761Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During PregnancyAmgen
- RECRUITINGPHASE3NCT05199688A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)Hoffmann-La Roche
- RECRUITINGPHASE4NCT07420296Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderTianjin Medical University General Hospital
- RECRUITINGNCT06885957Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSDTongji Hospital
- RECRUITINGPHASE1NCT06620809The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum DisordersTongji Hospital
- RECRUITINGNANCT06865274Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT06780709Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSDIcahn School of Medicine at Mount Sinai
- ACTIVE NOT RECRUITINGPHASE3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc.